Growth Triggers Line Up for Divi’s Labs

The stock of contract development and manufacturing organisation (CDMO) Divi’s Laboratories was among the top gainers in the BSE 100 index on Monday. It rose 4.81 per cent as its fourth-quarter revenues beat estimates across key segments, while margins hit multi-quarter highs.

The management has guided for double-digit growth for 2025-26 (FY26), which, coupled with stronger momentum from China+1 and the commercialisation of the blood sugar control drug glucagon-like peptide-1 (GLP-1), will act as key triggers. Brokerages, however, believe upsides are limited as valuations have turned expensive.

Divi’s posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range, this was on a higher base. Growth was led by the custom synthesis manufacturing (CSM) and generics segments, which grew by 12 per cent and 13 per cent, respectively.

 

Related Posts

Operation Monsoon Thunder: NCB raids four cities, arrests six in probe into US-bound opioid and psychotropic drug shipments

New Delhi: In a sweeping international crackdown, the Narcotics Control Bureau (NCB) and the US Drug Enforcement Administration (DEA) have dismantled the Indian nerve center of a massive transnational drug…

Maharashtra FDA issues statewide compliance order for health supplements, nutraceuticals

Commissioner of Food Safety Tukaram Mundhe said inspections, consumer complaints and surveillance had repeatedly revealed violations Repeated violations of existing food safety regulations by manufacturers and sellers of health supplements…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Operation Monsoon Thunder: NCB raids four cities, arrests six in probe into US-bound opioid and psychotropic drug shipments

Operation Monsoon Thunder: NCB raids four cities, arrests six in probe into US-bound opioid and psychotropic drug shipments

Maharashtra FDA issues statewide compliance order for health supplements, nutraceuticals

Maharashtra FDA issues statewide compliance order for health supplements, nutraceuticals

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines